【摘要】 目的 探讨多次进行人脐带间充质干细胞(human umbilical cord mesenchymal stem cells, HUC-MSCs)肝内移植及不同时间间隔治疗失代偿期肝硬化患者的临床疗效。方法 选取河南科技大学第一附属医院2021年02月-2023年12月失代偿期肝硬化自愿接受治疗患者51例，随机分为单次移植组、多次移植组和对照组，各17例。对比三组实验室指标、影像学检查以及不良反应发生率。结果 治疗前，三组肝功能及凝血功能指标差异均无统计学意义(P>0.05)；治疗后，多次移植组谷丙转氨酶、总胆红素低于单次移植组与对照组，白蛋白水平高于单次移植组与对照组，差异有统计学意义(P<0.05)；单次移植组白蛋白水平高于对照组，差异有统计学意义(P<0.05)。多次移植B组谷丙转氨酶、总胆红素低于A组，白蛋白高于A组，差异有统计学意义(P<0.05)。经影像学检查显示，多次移植组肝脏占位病变、门静脉血栓以及腹水发生率均低于单次移植组与对照组，差异有统计学意义(P<0.05)；单次移植组肝脏占位病变、门静脉血栓以及腹水发生率低于对照组，但差异无统计学意义(P>0.05)。所有患者治疗过程中均未出现严重不良反应，仅多次移植组术后发生2例发热，经对症处理后消失。三组不良反应对比差异无统计学意义(P>0.05)。结论 HUC-MSCs多次移植治疗肝硬化失代偿期患者具有良好的临床疗效，能够有效改善患者的肝脏功能，预防相关并发症的发生。同时，HUC-MSCs多次移植治疗的频率、间隔时间对疗效也有一定的影响，其中间隔3个月的疗效优于间隔1个月。更多还原

【Abstract】 Objective To investigate the clinical efficacy of multiple intrahepatic transplantation of human umbilical cord mesenchymal stem cells(HUCMSCs) and different time intervals for the treatment of patients with decompensated cirrhosis. Methods Fifty-one patients with decompensated cirrhosis who voluntarily received treatment in the First Affiliated Hospital of Henan University of Science and Technology from February 2021 to December 2023 were selected and randomly divided into the single transplantation group, the multiple transplantation group, and the control group, with 17 cases in each group. Laboratory indexes, imaging examinations and the incidence of adverse reactions were compared among the three groups. Results Before treatment, the differences in liver function and coagulation function indexes among the three groups were not statistically significant(P>0.05); after treatment, the glutamine transaminase and total bilirubin of the multiple transplantation group were lower than those of the single transplantation group and the control group, and the level of albumin was higher than those of the single transplantation group and the control group, with statistical significance(P<0.05); the level of albumin of the single transplantation group was higher than those of the control group, and the difference was statistically significant(P<0.05)). Glutamine transaminase and total bilirubin were lower and albumin was higher in multiple transplantation group B than group A. The difference was statistically significant(P<0.05). Imaging examination showed that the incidence of liver-occupying lesions, portal vein thrombosis and ascites in the multiple transplantation group was lower than that in the single transplantation group and the control group, with a statistically significant difference(P<0.05); the incidence of liver-occupying lesions, portal vein thrombosis and ascites in the single transplantation group was lower than that in the control group, but the difference was not statistically significant(P>0.05). No serious adverse reactions occurred during the treatment of all patients, and only two cases of postoperative fever occurred in the multiple transplantation group, which disappeared after symptomatic treatment. The difference in adverse reactions among the three groups was not statistically significant(P>0.05). Conclusion Multiple transplantation of HUC-MSCs for the treatment of patients with decompensated cirrhosis has good clinical efficacy, which can effectively improve the liver function of patients and prevent the occurrence of related complications. Meanwhile, the frequency and interval of HUC-MSCs multiple transplantation also have some influence on the efficacy, in which the efficacy of 3-month interval is better than 1-month interval.更多还原